| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adipose Tissue | 31 | 2020 | 320 | 5.240 |
Why?
|
| Stem Cells | 14 | 2020 | 321 | 2.230 |
Why?
|
| Stromal Cells | 14 | 2020 | 66 | 1.860 |
Why?
|
| Cell Differentiation | 23 | 2020 | 461 | 1.840 |
Why?
|
| Adipocytes | 13 | 2015 | 69 | 1.570 |
Why?
|
| Cell Culture Techniques | 7 | 2013 | 170 | 1.060 |
Why?
|
| Stem Cell Transplantation | 3 | 2015 | 221 | 0.930 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2020 | 73 | 0.850 |
Why?
|
| Surgery, Plastic | 3 | 2019 | 29 | 0.840 |
Why?
|
| Lipectomy | 5 | 2017 | 8 | 0.840 |
Why?
|
| Mesenchymal Stem Cells | 6 | 2020 | 165 | 0.810 |
Why?
|
| Wound Healing | 5 | 2020 | 185 | 0.800 |
Why?
|
| Osteogenesis | 6 | 2016 | 79 | 0.770 |
Why?
|
| Mammaplasty | 2 | 2019 | 26 | 0.730 |
Why?
|
| Tissue Engineering | 5 | 2015 | 695 | 0.700 |
Why?
|
| Spheroids, Cellular | 3 | 2013 | 36 | 0.700 |
Why?
|
| Neovascularization, Physiologic | 5 | 2020 | 114 | 0.680 |
Why?
|
| Regenerative Medicine | 4 | 2020 | 217 | 0.650 |
Why?
|
| Cells, Cultured | 15 | 2020 | 839 | 0.640 |
Why?
|
| Regeneration | 5 | 2017 | 178 | 0.610 |
Why?
|
| Embolism, Fat | 1 | 2019 | 1 | 0.600 |
Why?
|
| Buttocks | 1 | 2019 | 5 | 0.600 |
Why?
|
| Workload | 1 | 2019 | 32 | 0.590 |
Why?
|
| Humans | 46 | 2020 | 32284 | 0.560 |
Why?
|
| Burnout, Professional | 1 | 2019 | 54 | 0.550 |
Why?
|
| Cell Separation | 3 | 2017 | 89 | 0.550 |
Why?
|
| Animals | 24 | 2020 | 8199 | 0.520 |
Why?
|
| Adipogenesis | 6 | 2016 | 30 | 0.500 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 44 | 0.500 |
Why?
|
| Collagen | 3 | 2012 | 229 | 0.480 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 60 | 0.440 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 53 | 0.430 |
Why?
|
| Pressure Ulcer | 3 | 2020 | 8 | 0.430 |
Why?
|
| Adult Stem Cells | 2 | 2011 | 26 | 0.410 |
Why?
|
| Proteome | 2 | 2013 | 41 | 0.400 |
Why?
|
| Subcutaneous Fat | 2 | 2016 | 44 | 0.380 |
Why?
|
| Cell Movement | 3 | 2012 | 167 | 0.380 |
Why?
|
| Burns | 2 | 2017 | 102 | 0.380 |
Why?
|
| Tissue Scaffolds | 3 | 2012 | 431 | 0.370 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 23 | 0.360 |
Why?
|
| Guided Tissue Regeneration | 1 | 2012 | 39 | 0.360 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2011 | 6 | 0.350 |
Why?
|
| Culture Media | 2 | 2012 | 48 | 0.340 |
Why?
|
| Biocompatible Materials | 2 | 2012 | 240 | 0.340 |
Why?
|
| Risk Management | 1 | 2011 | 22 | 0.330 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 390 | 0.320 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2010 | 17 | 0.320 |
Why?
|
| Stem Cell Niche | 1 | 2010 | 24 | 0.310 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 762 | 0.310 |
Why?
|
| Mice | 10 | 2020 | 2571 | 0.300 |
Why?
|
| Multipotent Stem Cells | 2 | 2007 | 16 | 0.300 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 104 | 0.300 |
Why?
|
| Rats | 9 | 2020 | 1895 | 0.300 |
Why?
|
| Mesentery | 2 | 2008 | 6 | 0.300 |
Why?
|
| Flow Cytometry | 6 | 2017 | 184 | 0.290 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 100 | 0.280 |
Why?
|
| Poloxamer | 1 | 2008 | 4 | 0.280 |
Why?
|
| Surface-Active Agents | 1 | 2008 | 7 | 0.280 |
Why?
|
| Organ Transplantation | 1 | 2009 | 67 | 0.280 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 85 | 0.270 |
Why?
|
| Microcirculation | 1 | 2008 | 66 | 0.270 |
Why?
|
| Mastectomy | 2 | 2019 | 59 | 0.270 |
Why?
|
| Culture Media, Serum-Free | 2 | 2008 | 15 | 0.270 |
Why?
|
| Cell Transplantation | 2 | 2009 | 65 | 0.250 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2019 | 191 | 0.240 |
Why?
|
| Adult | 11 | 2019 | 9259 | 0.240 |
Why?
|
| Antigens, Surface | 1 | 2005 | 25 | 0.220 |
Why?
|
| Chondrogenesis | 3 | 2012 | 19 | 0.210 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 315 | 0.200 |
Why?
|
| RNA, Messenger | 3 | 2016 | 499 | 0.190 |
Why?
|
| Middle Aged | 9 | 2019 | 11853 | 0.180 |
Why?
|
| Pericytes | 2 | 2013 | 32 | 0.180 |
Why?
|
| Cell Line | 5 | 2017 | 454 | 0.170 |
Why?
|
| Female | 14 | 2020 | 19947 | 0.170 |
Why?
|
| Fibronectins | 3 | 2017 | 39 | 0.170 |
Why?
|
| Male | 11 | 2020 | 19443 | 0.170 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2001 | 35 | 0.170 |
Why?
|
| Sciatic Neuropathy | 1 | 2010 | 15 | 0.160 |
Why?
|
| Omentum | 1 | 2010 | 25 | 0.160 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 1083 | 0.160 |
Why?
|
| Nerve Regeneration | 1 | 2010 | 50 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 68 | 0.160 |
Why?
|
| Time Factors | 4 | 2011 | 2205 | 0.160 |
Why?
|
| Esthetics | 1 | 2019 | 10 | 0.150 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 11 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 39 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2012 | 897 | 0.140 |
Why?
|
| Cell Lineage | 4 | 2009 | 65 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2020 | 193 | 0.140 |
Why?
|
| Skin | 3 | 2020 | 212 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 91 | 0.140 |
Why?
|
| Tissue Preservation | 2 | 2011 | 8 | 0.130 |
Why?
|
| Fluorescein | 1 | 2017 | 1 | 0.130 |
Why?
|
| Lymphatic System | 1 | 2017 | 3 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 179 | 0.130 |
Why?
|
| Lymphedema | 1 | 2017 | 5 | 0.130 |
Why?
|
| Cicatrix | 1 | 2017 | 39 | 0.130 |
Why?
|
| Cell Proliferation | 3 | 2009 | 603 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3416 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 893 | 0.130 |
Why?
|
| Cryopreservation | 2 | 2020 | 52 | 0.120 |
Why?
|
| Adipocytes, White | 1 | 2016 | 2 | 0.120 |
Why?
|
| Thermogenesis | 1 | 2016 | 4 | 0.120 |
Why?
|
| BRCA1 Protein | 2 | 2006 | 6 | 0.120 |
Why?
|
| Aromatase | 2 | 2006 | 12 | 0.120 |
Why?
|
| Mesoderm | 3 | 2006 | 12 | 0.120 |
Why?
|
| Cell Survival | 2 | 2014 | 288 | 0.120 |
Why?
|
| Rats, Nude | 2 | 2013 | 48 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 75 | 0.120 |
Why?
|
| Bone Marrow Cells | 2 | 2017 | 114 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2015 | 17 | 0.110 |
Why?
|
| Achievement | 1 | 2015 | 3 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 32 | 0.110 |
Why?
|
| Efficiency | 1 | 2015 | 17 | 0.110 |
Why?
|
| Awards and Prizes | 1 | 2015 | 12 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 19 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 478 | 0.110 |
Why?
|
| Muscle, Skeletal | 3 | 2013 | 520 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 51 | 0.110 |
Why?
|
| Mitochondria | 1 | 2016 | 211 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2019 | 823 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 153 | 0.100 |
Why?
|
| Extracellular Matrix | 3 | 2020 | 256 | 0.100 |
Why?
|
| Fibroblasts | 4 | 2020 | 119 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 942 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 1425 | 0.100 |
Why?
|
| Cell Hypoxia | 2 | 2011 | 43 | 0.100 |
Why?
|
| Paracrine Communication | 1 | 2013 | 5 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 27 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 50 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 2649 | 0.100 |
Why?
|
| Osteocytes | 1 | 2013 | 4 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2013 | 84 | 0.100 |
Why?
|
| Calcification, Physiologic | 1 | 2013 | 8 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2010 | 41 | 0.100 |
Why?
|
| Retina | 1 | 2013 | 86 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 108 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 10 | 0.090 |
Why?
|
| Aged | 4 | 2018 | 10265 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2012 | 21 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 12 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 246 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 109 | 0.090 |
Why?
|
| Random Allocation | 1 | 2012 | 247 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 100 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2011 | 23 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2011 | 285 | 0.080 |
Why?
|
| Tendon Injuries | 1 | 2011 | 36 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2011 | 477 | 0.080 |
Why?
|
| Cell Aggregation | 1 | 2010 | 3 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 13 | 0.080 |
Why?
|
| Transgenes | 1 | 2010 | 46 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 34 | 0.080 |
Why?
|
| Organ Culture Techniques | 1 | 2010 | 44 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 98 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 150 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 423 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 3519 | 0.070 |
Why?
|
| P-Selectin | 1 | 2009 | 10 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 203 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 39 | 0.070 |
Why?
|
| Inflammation | 2 | 2011 | 506 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 545 | 0.070 |
Why?
|
| Isotonic Solutions | 1 | 2008 | 5 | 0.070 |
Why?
|
| Nanostructures | 1 | 2008 | 20 | 0.070 |
Why?
|
| Biomimetic Materials | 1 | 2008 | 15 | 0.070 |
Why?
|
| Ischemia | 1 | 2009 | 115 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 38 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 907 | 0.070 |
Why?
|
| Immunophenotyping | 3 | 2017 | 47 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2008 | 57 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 142 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 186 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 236 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 293 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 792 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2008 | 164 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2019 | 74 | 0.060 |
Why?
|
| Serum | 1 | 2007 | 14 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 408 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 27 | 0.060 |
Why?
|
| Telomerase | 1 | 2005 | 20 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 84 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 58 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 160 | 0.050 |
Why?
|
| Osteoblasts | 3 | 2016 | 43 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 140 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 146 | 0.050 |
Why?
|
| Protein Binding | 2 | 2017 | 244 | 0.050 |
Why?
|
| Obesity | 3 | 2016 | 1111 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2001 | 28 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2010 | 20 | 0.040 |
Why?
|
| Equipment Design | 1 | 2001 | 178 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 111 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 42 | 0.040 |
Why?
|
| Microvessels | 1 | 2020 | 30 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2010 | 239 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 60 | 0.040 |
Why?
|
| Phenotype | 2 | 2013 | 622 | 0.040 |
Why?
|
| Mastectomy, Radical | 1 | 2018 | 1 | 0.040 |
Why?
|
| Publishing | 1 | 2019 | 66 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 25 | 0.040 |
Why?
|
| Cell Shape | 2 | 2008 | 28 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 729 | 0.030 |
Why?
|
| Skin Physiological Phenomena | 1 | 2017 | 7 | 0.030 |
Why?
|
| Axilla | 1 | 2017 | 17 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2017 | 14 | 0.030 |
Why?
|
| Microsurgery | 1 | 2017 | 21 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| L-Selectin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Glycosyltransferases | 1 | 2017 | 3 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 15 | 0.030 |
Why?
|
| E-Selectin | 1 | 2017 | 20 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2017 | 11 | 0.030 |
Why?
|
| Neuraminidase | 1 | 2017 | 8 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 66 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 34 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 90 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 100 | 0.030 |
Why?
|
| Adipocytes, Brown | 1 | 2016 | 2 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2016 | 20 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 23 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 33 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 33 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2016 | 54 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 368 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 193 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 299 | 0.030 |
Why?
|
| Tomography, Spiral Computed | 1 | 2015 | 19 | 0.030 |
Why?
|
| Authorship | 1 | 2015 | 9 | 0.030 |
Why?
|
| Financing, Organized | 1 | 2015 | 17 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 11 | 0.030 |
Why?
|
| Bibliometrics | 1 | 2015 | 11 | 0.030 |
Why?
|
| Mentors | 1 | 2015 | 33 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 62 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 171 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 191 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2015 | 76 | 0.030 |
Why?
|
| Echocardiography | 1 | 2015 | 190 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 25 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 504 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 164 | 0.020 |
Why?
|
| Reference Standards | 1 | 2013 | 28 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 48 | 0.020 |
Why?
|
| Retinal Vessels | 1 | 2013 | 27 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1840 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 96 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 72 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 727 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 138 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 222 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 258 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 2316 | 0.020 |
Why?
|
| Chondrocytes | 2 | 2003 | 70 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 603 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 74 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2240 | 0.020 |
Why?
|
| Scoliosis | 1 | 2010 | 20 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 63 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 97 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 471 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Anthraquinones | 1 | 2008 | 5 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2008 | 9 | 0.020 |
Why?
|
| Selectins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2008 | 16 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cell Count | 1 | 2008 | 51 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 40 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 75 | 0.020 |
Why?
|
| Liposarcoma | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lipoma | 1 | 2007 | 6 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 155 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2007 | 68 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 17 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 46 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2006 | 80 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2006 | 46 | 0.020 |
Why?
|
| Lung | 1 | 2008 | 263 | 0.020 |
Why?
|
| United States | 1 | 2015 | 4072 | 0.020 |
Why?
|
| Ovary | 1 | 2006 | 66 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 2005 | 11 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 55 | 0.010 |
Why?
|
| Estrogens | 1 | 2005 | 194 | 0.010 |
Why?
|
| Collagen Type II | 1 | 2003 | 8 | 0.010 |
Why?
|
| Viscera | 1 | 2003 | 13 | 0.010 |
Why?
|
| Osteonectin | 1 | 2003 | 5 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 15 | 0.010 |
Why?
|
| tau Proteins | 1 | 2003 | 39 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 183 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 12 | 0.010 |
Why?
|
| Biological Therapy | 1 | 2001 | 18 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 486 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 375 | 0.010 |
Why?
|